Immupharma (LON:IMM) shares dropped 0% on Wednesday . The company traded as low as GBX 28.20 ($0.38) and last traded at GBX 28.30 ($0.38). Approximately 6,601,193 shares changed hands during mid-day trading, an increase of 707% from the average daily volume of 817,845 shares. The stock had previously closed at GBX 28.30 ($0.38).

IMM has been the topic of a number of recent research reports. Northland Securities reissued a “buy” rating on shares of Immupharma in a report on Tuesday, April 17th. Berenberg Bank reissued a “buy” rating on shares of Immupharma in a report on Monday, April 16th. Finally, Northland Capital Partners reissued a “buy” rating and issued a GBX 181 ($2.43) target price on shares of Immupharma in a report on Friday, March 23rd.

About Immupharma

ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company's lead product candidate is the Lupuzor, which is in Phase III clinical trials for the treatment of lupus, an autoimmune chronic inflammatory disease.

Receive News & Ratings for Immupharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immupharma and related companies with MarketBeat.com's FREE daily email newsletter.